Application of STAT5A in sepsis targeted therapy medicine
Through targeted therapeutic drugs with STAT5A as a target, STAT5A gene expression is regulated and the production of inflammatory mediators is inhibited, the problem of poor prognosis of sepsis is solved, the survival rate and treatment effect of patients are improved, and the accuracy of sepsis is achieved. Therapy provides technical support.
Patent Information
- Application Number
- CN202410998973.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-24
- Publication Date
- 2024-11-08
AI Technical Summary
The poor prognosis of sepsis is mainly due to insufficient understanding of the molecular mechanisms of disease occurrence and development, and the key targets are still unclear, resulting in poor treatment results.
By screening out the key gene STAT5A related to the prognosis of septic patients, developing targeted therapeutic drugs with STAT5A as a target, regulating STAT5A gene expression to inhibit the production and release of inflammatory mediators, and improving patient survival and prognosis.
The application of STAT5A as a new target has significantly improved the survival rate of sepsis patients, reduced mortality, and provided technical support for precise treatment, filling the gap in the absence of key targets in clinical practice.
Smart Images

Figure CN118903426A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to application of STAT5A in targeted therapeutic drugs for sepsis. Background Art
[0002] Sepsis is a common clinical critical illness, defined as a state of immune disorder in which severe inflammatory infection leads to damage to the function of two or more organs. Approximately 19 million people worldwide develop sepsis each year, with a mortality rate as high as 30%. If accompanied by septic shock, the mortality rate can reach 80%. Currently, the treatment of sepsis mainly consists of comprehensive treatments such as anti-infection, fluid resuscitation, and maintenance of multi-organ function. However, even with advanced support technologies such as extracorporeal membrane oxygenation (ECMO), the prognosis of sepsis remains poor.
[0003] The poor prognosis of sepsis is primarily due to our inadequate understanding of the molecular mechanisms underlying the disease's development and progression. Currently, only a few studies have systematically investigated the prognosis of sepsis patients. However, the key targets of sepsis remain largely unknown. Therefore, this study aims to identify key genes associated with sepsis prognosis, providing technical support for research into sepsis prognosis and precision medicine.
[0004] To this end, the present invention aims to provide the use of STAT5A in targeted therapeutic drugs for sepsis to solve the above problems. Summary of the Invention
[0005] The purpose of the present invention is to solve the above problems and provide the application of STAT5A in sepsis targeted therapeutic drugs.
[0006] In order to achieve the above object, the technical solution of the present invention is as follows:
[0007] The present invention provides an application of a STAT5A gene as a target in the preparation of a drug for treating sepsis.
[0008] Furthermore, the drug for treating sepsis is used to treat sepsis caused by pneumonia, digestive system infection, peritonitis, cholangitis, urinary system infection, cellulitis, bacteremia or multiple trauma diseases.
[0009] It should be noted that sepsis can be divided into sepsis, severe sepsis, and septic shock according to its severity. Sepsis refers to a systemic inflammatory response syndrome caused by a clear or suspected infection. Its etiology is mainly caused by bacteria, fungi, viruses, and parasites, which can cause infection and lead to sepsis, which is common in patients with severe trauma or infectious diseases. Infection can cause a systemic inflammatory response, and its onset is related to the body's inflammatory response and immune regulation imbalance. Sepsis is often caused by various types of trauma and infection, and is common in diseases such as pneumonia, digestive tract infection, peritonitis, cholangitis, urinary tract infection, cellulitis, bacteremia, and multiple trauma. After the body is infected, bacteria and toxins enter the body, activate the body's inflammatory response cells, produce and release large amounts of inflammatory mediators (such as TNF-α, IL-1β, IL-6, etc.), and cause local or systemic inflammatory responses.
[0010] Furthermore, the drug for treating sepsis targets the STAT5A gene and upregulates the expression of the STAT5A gene.
[0011] Furthermore, the upregulation of STAT5A gene expression is achieved by upregulating the expression of RAD51, OSM, RNMT, MET, IFNG, BCL6, IL6ST, FCGR1A, CITED2, CEL, BCL2L1, MYD88, PRF1, MUC1, ZNF395 or LONP1 genes.
[0012] Furthermore, the drug for treating sepsis inhibits the production and release of inflammatory mediators by regulating STAT5A gene expression, and the inflammatory mediators include TNF-α, IL-1β and IL-6.
[0013] Furthermore, the dosage form of the drug for treating sepsis is tablets, capsules, liquid preparations, lozenges, aerosols, injections, ointments or granules.
[0014] The present invention also provides an application of the STAT5A gene in preparing a drug for regulating the production and release of inflammatory mediators.
[0015] Compared with the prior art, the solution of the present invention has the following beneficial effects:
[0016] By comparing PBMC gene sequencing between sepsis patients and healthy controls, the present invention found that STAT5A was underexpressed in the sepsis group. By downloading multiple data sets for meta-analysis of STAT5A, it was found that STAT5A was decreased in the sepsis death group and highly expressed in the survival group. Further analysis of the clinical and genetic data of the data set GSE65682 revealed that in sepsis, patients with high expression had a higher survival rate, while the low expression group had a higher mortality rate. In addition, linear correlation analysis of the Apache II score, which measures the severity of clinical sepsis symptoms, revealed that STAT5A was negatively correlated with disease severity.
[0017] The present invention provides STAT5A as a new target for the development of drugs to treat sepsis, which is caused by infection, activation of the body's inflammatory response cells, production and release of large amounts of inflammatory mediators, aggravated inflammatory response and profound suppression of immune function. This fills the gap in the clinical understanding of key targets for sepsis and provides technical support for the research on sepsis prognosis and precision treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 is the PBMC gene sequencing result of sepsis patients and normal subjects in the embodiment of the present invention;
[0019] Figure 2 This is the result of a meta-analysis of STAT5A using multiple data sets in the examples of the present invention;
[0020] Figure 3 This is the analysis result of clinical survival rate and STAT5A gene data of the dataset GSE65682 in the embodiment of the present invention;
[0021] Figure 4 is the linear correlation analysis result of ApacheⅡ score of clinical symptom severity in the embodiment of the present invention;
[0022] Figure 5 is the single-cell sequencing analysis result in an embodiment of the present invention;
[0023] Figure 6 This is the result of knocking out the STAT5A gene in the embodiment of the present invention;
[0024] Figure 7 This is the analysis result of STAT5A downstream target genes in the examples of the present invention. DETAILED DESCRIPTION
[0025] In order to enable those skilled in the art to better understand the present invention, the technical solution of the present invention will be further described in detail below in conjunction with the embodiments of the present invention and the accompanying drawings. Obviously, the embodiments described are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative efforts should fall within the scope of protection of the present invention.
[0026] It should be noted that, in the absence of conflict, the embodiments and features of the embodiments of the present invention can be combined with each other. The present invention will be described in detail below with reference to the embodiments.
[0027] Example:
[0028] The following is a specific implementation and test of the embodiment of the present invention:
[0029] 1. PBMC gene sequencing of sepsis patients and healthy subjects
[0030] By performing RNA-seq sequencing on peripheral blood samples from 23 sepsis patients and 10 normal subjects, the original data were log2 processed, and the STAT5A sequencing data of the two groups of patients were statistically analyzed by t-test, and the expression value comparison chart between the two groups of patients was obtained ( Figure 1 ), Figure 1 The results showed that the expression of STAT5A in the sepsis group was lower than that in the normal (NC) group.
[0031] 2. Download multiple data sets for meta-analysis of STAT5A
[0032] By downloading the gene chip or sequencing datasets GSE54514, GSE63042, and GSE95233 from the GEO public database, we extracted the expression values of STAT5A in the three study data, divided them into survival and death groups, and then used a meta-analysis strategy for integrated analysis. After the meta-analysis method was used to expand the sample size, we explored whether there was a difference in STAT5A between the survival and death groups (see Figure 2 ). Figure 2 The results suggested that STAT5A expression was decreased in the sepsis death group and higher in the survival group than in the death group.
[0033] 3. Clinical and genetic data analysis of dataset GSE65682
[0034] The GSE65682 gene dataset was downloaded from GEO. This dataset contains the peripheral blood gene expression patterns and 28-day survival prognosis of 478 sepsis patients. STAT5A expression values were sorted from small to large, with the top half as the low-expression group and the bottom half as the high-expression group. Survival analysis was performed using GraphPad Pism 9.5 software, combined with the patient's prognosis and survival. A log-rank P value of <0.05 was defined as statistically significant (see Figure 3 ). Figure 3 The results showed that the survival rate of patients in the high-expression group of STAT5A in sepsis was higher, while the mortality rate was higher in the low-expression group. In other words, the prognosis of the high-expression group of STAT5A in sepsis was significantly better than that of the death group.
[0035] 4. Linear correlation analysis of Apache II score and clinical symptom severity
[0036] The linear correlation analysis was performed using the Apache II score of the severity of sepsis patients in GSE54514 and the STAT5A expression value of the patients (see Figure 4 ). Figure 4 The results showed that the higher the STAT5A expression value, the lower the ApacheⅡ score (representing a milder condition), and it was negatively correlated with the severity of sepsis patients.
[0037] 5. Single-cell sequencing analysis
[0038] Peripheral blood is a mixed cell population. To further investigate which cell lines primarily express STAT5A and clarify the cell line localization problem, 10× single-cell sequencing analysis and tSNE dimensionality reduction were performed on peripheral blood PBMC cells from 2 normal subjects, 1 SIRS patient, and 2 sepsis patients. After identifying the cell lines using characteristic biomarkers, the expression values of STAT5A were visualized (see Figure 5 ). Figure 5 The results showed that STAT5A was mainly located in the macrophage cell line.
[0039] 6. Gene knockout technology analysis
[0040] sgRNA was designed using CRISPR / Cas technology, and STAT5A gene knockout mice were obtained by high-throughput electroporation of fertilized eggs. Sperm was collected after sexual maturity and frozen. Survival curve analysis was performed using 6-8 week old homologous mice, with 10 mice per group. Normal mice were classified as WT group, while STAT5A gene knockout group was defined as STAT5A- / - group. Sepsis model was established by intraperitoneal injection of LPS (20 mg / kg), and the survival time and activity of mice were recorded for 7 days (see Figure 6 ). Figure 6The results showed that through gene knockout technology, the mortality rate of septic mice in the knockout group was 100%, while the mortality rate in the non-knockout group was significantly reduced to 50%.
[0041] 7. Analysis of the regulatory function of STAT5A
[0042] To further understand which target genes STAT5A regulates to achieve its protective function in promoting the survival of patients with sepsis, we used bioinformatics methods combined with the patient prognosis of each gene to find that STAT5A, as a transcription factor, mainly regulates the function of downstream target genes. Specifically, it was found that STAT5A is involved in regulating the transcription of RAD51, OSM, RNMT, MET, IFNG, BCL6, IL6ST, FCGR1A, CITED2, CEL, BCL2L1, MYD88, PRF1, MUC1, ZNF395 or LONP1 genes (see Figure 7 ).
[0043] In summary, the present invention found that STAT5A was lowly expressed in the sepsis group by comparing PBMC gene sequencing of sepsis patients and normal subjects, and by downloading multiple data sets for meta-analysis of STAT5A, it was found that STAT5A was reduced in the sepsis death group and highly expressed in the survival group. Further analysis of the clinical and genetic data of the data set GSE65682 showed that in sepsis, patients with high expression had a higher survival rate, while the mortality rate of the low expression group was higher. In addition, the linear correlation analysis of the ApacheⅡ score of the severity of clinical sepsis symptoms showed that STAT5A was negatively correlated with the severity of the disease. The application of STAT5A provided by the present invention as a new target in the development of drugs for treating sepsis caused by infection, activation of the body's inflammatory response cells, production and release of a large amount of inflammatory mediators, exacerbation of inflammatory response and deep suppression of immune function has filled the gap in the clinical key targets of sepsis, and provides technical support for the research on sepsis prognosis and precision treatment.
[0044] The above-described embodiments merely represent preferred embodiments of the present invention, and their descriptions are relatively specific and detailed, but they should not be construed as limiting the scope of the present invention. It should be noted that a person skilled in the art may make various modifications and improvements without departing from the spirit of the present invention, and such modifications and improvements fall within the scope of protection of the present invention. Therefore, the scope of protection of the present invention shall be determined by the appended claims.
Claims
1. Application of STAT5A gene as a target in the preparation of drugs for the treatment of sepsis.
2. The use according to claim 1, It is characterized in that The drug for treating sepsis is used to treat sepsis caused by pneumonia, digestive system infection, peritonitis, cholangitis, urinary system infection, cellulitis, bacteremia or multiple trauma diseases.
3. The use according to claim 2, It is characterized in that The drug for treating sepsis takes the STAT5A gene as a target and upregulates the expression of the STAT5A gene.
4. The use according to claim 3, It is characterized in that The upregulation of STAT5A gene expression is achieved by upregulating RAD51, OSM, RNMT, MET, IFNG, BCL6, IL6ST, FCGR1A, CITED2, CEL, BCL2L1, MYD88, PRF1, MUC1, ZNF395 or LONP1 gene expression.
5. The use according to claim 2, It is characterized in that The drug for treating sepsis inhibits the production and release of inflammatory mediators by regulating the expression of STAT5A gene, and the inflammatory mediators include TNF-α, IL-1β and IL-6.
6. The use according to any one of claims 2 to 5, It is characterized in that The dosage form of the drug for treating sepsis is tablets, capsules, liquid medicines, lozenges, aerosols, injections, ointments or granules.
7. Use of a STAT5A gene in the preparation of a drug for regulating the production and release of inflammatory mediators.
